X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, Abbvie expands neuroscience pipeline with multiple clinical-stage and preclinical candidates, including CVL-231 (emraclidine), with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $8,700.0 million Upfront Cash: $8,700.0 million
Deal Type: Acquisition December 06, 2023
Details:
Emraclidine is a positive allosteric modulator designed to selectively target the M4 muscarinic receptor subtype. Emerging evidence suggests that activation of M4 muscarinic acetylcholine receptor subtypes can reduce striatal dopamine signaling and reduce psychotic symptoms.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
CVL-231 (emraclidine), is a positive allosteric modulator designed to selectively target the M4 muscarinic receptor subtype. Emerging evidence suggests that activation of M4 muscarinic acetylcholine receptor subtypes can reduce striatal dopamine signaling.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Cerevel intends to use the net proceeds to accelerate market development and pre-commercial planning activities for emraclidine and tavapadon, to advance the remainder of the programs in its pipeline, including darigabat, and its other promising earlier-stage programs.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley & Co
Deal Size: $254.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 12, 2022
Details:
Cerevel intends to use the net proceeds to support the continued development of emraclidine, including to accelerate registration-enabling activities, to evaluate the potential of emraclidine in other populations, including Alzheimer’s disease psychosis.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
